Evidence map›Paper›PMID 41040207›Full record

ArticlebioRxiv : the preprint server for biology2025

Structure-Guided Development of a Potent BioA Inhibitor Validates Biotin Synthesis Inhibition as a Therapeutic Strategy for Tuberculosis.

Qiang Liu, Joshua B Wallach, Yahani P Jayasinghe, Mark R Sullivan, Julianna Proietto, Suyapa Rodriguez, Sang Vo, Helena I M Boshoff, Ziyi Jia, Lev Ostrer and 9 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Qiang LiuDepartment of Medicinal Chemistry, University of Minnesota, 308 Harvard Street SE, Minneapolis, Minnesota 55455, United States.
Joshua B WallachDepartment of Microbiology and Immunology, Weill Cornell Medical College, 1300 York Avenue, New York 10021, United States.
Yahani P JayasingheDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States.
Mark R SullivanDepartment of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
Julianna ProiettoCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, United States.
Suyapa RodriguezCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, United States.
Sang VoDepartment of Medicinal Chemistry, University of Minnesota, 308 Harvard Street SE, Minneapolis, Minnesota 55455, United States.
Helena I M BoshoffTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Rockville Pike, Bethesda, Maryland 9000, United States.
Ziyi JiaDepartment of Microbiology & Immunology, University of Minnesota Medical School, Minneapolis, MN 55455, United States.
Lev OstrerDepartment of Microbiology & Immunology, University of Minnesota Medical School, Minneapolis, MN 55455, United States.
Kritee MehdirattaDepartment of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
Rui ShiDepartment of Medicinal Chemistry, University of Minnesota, 308 Harvard Street SE, Minneapolis, Minnesota 55455, United States.
Véronique DartoisCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, United States.
Anthony D BaughnDepartment of Microbiology & Immunology, University of Minnesota Medical School, Minneapolis, MN 55455, United States.
Eric J RubinDepartment of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
Donald R RonningDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States.
Matthew D ZimmermanCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, United States.
Dirk SchnappingerDepartment of Microbiology and Immunology, Weill Cornell Medical College, 1300 York Avenue, New York 10021, United States.
Courtney C AldrichDepartment of Medicinal Chemistry, University of Minnesota, 308 Harvard Street SE, Minneapolis, Minnesota 55455, United States.

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
Targeting Biotin Metabolism in Mycobacterium TuberculosisR01AI143784 · NIAID · UNIVERSITY OF MINNESOTA · PI ALDRICH, COURTNEY C, DARTOIS, VERONIQUE · 2019 to 2023
$3.9M
NCI NIH HHS P30 CA077598NIAID NIH HHS R01 AI143784
6 · The paper itself

Abstract

Structure-guided optimization was applied to develop a potent and selective inhibitor of the aminotransferase BioA, a key enzyme in bacterial biotin biosynthesis. Strategic modifications of a screening hit enhanced potency and pharmacokinetics, yielding

Identifiers

PMID41040207
PMCPMC12485673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.